




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Cardiac Surgery</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=7477ae68-a2db-444b-a0b2-e21d88347930</link>
        <description>Clinical Topic Feed: Cardiac Surgery</description>
        <language>en</language>

        

                <item>
                    <title>Does Early Surgery For Patients With Severe AS Lower CV Mortality Risk?</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/04/15/17/20/Does-Early-Surgery</link>                    <description>Early surgical aortic valve replacement (SAVR) led to a lower incidence of operative mortality or cardiovascular-related death at 10 years in patients with very severe aortic stenosis (AS), according to an extended follow-up of the RECOVERY trial published March 25 in NEJM.</description>
                    <pubdate>1776358260000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Transcatheter Aortic Valve Implantation: Durability and Management of Valve Failure</title>
<link>/Latest-in-Cardiology/Articles/2026/04/13/18/35/Transcatheter-Aortic-Valve-Implantation</link>                    <description>Transcatheter aortic valve implantation (TAVI) has become a cornerstone therapy for patients with severe aortic stenosis across a wide spectrum of clinical presentations and surgical risk. Initially reserved for patients at prohibitive or high surgical risk, TAVI is now widely adopted in populations at intermediate and low risk...</description>
                    <pubdate>1776119820000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Clinical Practice Algorithm For the Follow-Up of Unrepaired and Repaired Tetralogy of Fallot</title>
<link>/Latest-in-Cardiology/Articles/2024/10/30/13/20/Clinical-Practice-Algorithm-For-the-Follow-Up-of-Unrepaired-and-Repaired-ToF</link>                    <description>Tetralogy of Fallot (TOF) is the most common form of cyanotic congenital heart disease (CHD). Early management of this condition is typically dictated by the degree of pulmonary stenosis (PS) and resulting oxygen saturations.</description>
                    <pubdate>1775976060000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Top Takeaways from ACC.26</title>
<link>/Latest-in-Cardiology/Articles/2026/04/08/13/19/eagles-eye-view-08apr2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30.</description>
                    <pubdate>1775654580000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Management of a Patient With Fontan Procedure in the Cardiac Intensive Care Unit</title>
<link>/Education-and-Meetings/Patient-Case-Quizzes/2026/04/06/17/15/Management-of-a-Patient-With-Fontan-Procedure-in-the-Cardiac-Intensive-Care-Unit</link>                    <description>A 19-year-old man presents to the emergency department (ED) with fevers and an increasingly productive cough. He states that he had a &quot;cardiac surgery when he was a baby&quot; but does not know the specific procedure and has been lost to follow-up since 7 years of age.</description>
                    <pubdate>1775502840000</pubdate>
                    <category>Educational Activities</category>
                </item>
                <item>
                    <title>Mission in Action | Medtronic Clinician Update on New Evolut Valve Data Reinforces Need For Patient Dialogue</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Mission-in-Action-Medtronic-Clinician-Update</link>                    <description>New long-term data from the Evolut Low Risk trial published in JACC underscore how emerging science and evidence continue to shape patient-centered care in structural heart disease &#226;€“ an approach central to the ACC&#39;s Vision of using science, knowledge and innovation to optimize patient care and outcomes.</description>
                    <pubdate>1775045220000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Featured Jobs For April 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1775037480000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PRO-TAVI: Should High-Risk Patients Undergo PCI Before TAVI?</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protavi-acc-2026</link>                    <description>Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session...</description>
                    <pubdate>1774818600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PROTECT H2H: Emboliner vs. Sentinel Embolic Protection Devices in TAVR</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protecth2h-acc-2026</link>                    <description>In the first head-to-head comparison of two embolic protection devices used during TAVR, the investigational Emboliner protection catheter performed comparably to the U.S. Food and Drug Administration (FDA)-approved Sentinel cerebral protection system relative to the composite primary endpoint and secondary endpoint of stroke, according to results from the PROTECT H2H trial presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans.</description>
                    <pubdate>1774818180000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SURVIV: mViV vs. rMVR For Mitral Bioprosthetic Valve Dysfunction</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-surviv-acc-2026</link>                    <description>Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with standard repeat mitral valve replacement surgery (rMVR), according to results from the SURVIV study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans.</description>
                    <pubdate>1774818000000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>